Patent: 7,422,739
✉ Email this page to a colleague
Summary for Patent: 7,422,739
Title: | Anti-CD20 antibodies |
Abstract: | Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. |
Inventor(s): | Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA) |
Assignee: | Biogen Idec Inc. (Cambridge, MA) |
Application Number: | 09/911,703 |
Patent Claims: | see list of patent claims |
Details for Patent 7,422,739
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Acrotech Biopharma Inc. | ZEVALIN | ibritumomab tiuxetan | Injection | 125019 | February 19, 2002 | ⤷ Sign Up | 2012-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,422,739
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 938466 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 9411026 | ⤷ Sign Up |
United States of America | 7744877 | ⤷ Sign Up |
United States of America | 7381560 | ⤷ Sign Up |
United States of America | 6682734 | ⤷ Sign Up |
United States of America | 6399061 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |